Figure legends:
Figure 1. Untargeted metabolic profiles discriminate in different
inflammatory asthma phenotypes and healthy subjects in the discovery
set. (A-D) Score plot of PCA model obtained from different inflammatory
asthma phenotypes and healthy subjects retrospectively; (E-H) Score plot
of OPLS-DA model obtained from different inflammatory asthma phenotypes
and healthy subjects retrospectively; The labels t[1] and t[2]
along the axes represent the scores (the first 2 partial least-squares
components) of the model, which are sufficient to build a satisfactory
classification model. (I-L) Permutation Test of the OPLS-DA model
obtained from different inflammatory asthma phenotypes and healthy
subjects retrospectively; Two hundred permutations were performed, and
the resulting R2 and Q2 values were
plotted.
Figure 2. Heatmap of identified differential metabolites in sputum
samples in different inflammatory asthma phenotypes and healthy subjects
in the discovery set
Figure 3. MetaboAnalyst Pathway Impact based on selected and more
representative metabolites responsible for the class separation in
sputum samples in different asthma phenotypes and healthy subjects. (A)
Asthma and Healthy; (B) EA and NA; (C) EA and PGA; (D) NA and PGA.
Circles represent metabolic pathways potentially involved in class
separation. EA, eosinophilic asthma; NA, neutrophilic asthma; PGA,
paucigranulocytic asthma.
Figure 4. The receiver operating characteristic (ROC) curves of
metabolites to discriminate between NA and EA (A) or between NA and PGA
(B). EA, eosinophilic asthma; NA, neutrophilic asthma; PGA,
paucigranulocytic asthma.
Figure 5. Heatmap of correlations of differential metabolites with
clinical and inflammatory profiles in all subjects with asthma in the
validation set